Abstract
There is considerable evidence that T-helper 2 (Th2) cells play a central role in the pathogenesis of allergic diseases such as bronchial asthma, hay fever or food allergy. The differentiation of naïve T cells into Th2 cells producing a specific pattern of cytokines is tightly controlled and regulated by transcription factors. Thus down-regulation of mRNAlevels of a single transcription factor leads to a “knock-down” of several mediators simultaneously, representing an advantage compared to earlier approaches involving down-regulation of one intercellular inflammatory mediator, which is unlikely to influence all pathophysiological aspects of the disease. We review the impact of specific and master transcription factors involved in Th2 cell commitment and evaluate approaches for the down-regulation of these proteins by degradation of their mRNA using nucleic-acid based technologies including antisense oligonucleotides, ribozymes, DNAzymes, decoys oligonucleotides and RNA interference.
Keywords: Nucleic-acid based technology, antisense, therapeutic tool, transcription factor, allergy, asthma
Current Pharmaceutical Design
Title: Treatment of Allergic Asthma by Targeting Transcription Factors Using Nucleic-Acid Based Technologies
Volume: 12 Issue: 25
Author(s): Serdar Sel, Wolfgang Henke, Alexander Dietrich, Udo Herz and Harald Renz
Affiliation:
Keywords: Nucleic-acid based technology, antisense, therapeutic tool, transcription factor, allergy, asthma
Abstract: There is considerable evidence that T-helper 2 (Th2) cells play a central role in the pathogenesis of allergic diseases such as bronchial asthma, hay fever or food allergy. The differentiation of naïve T cells into Th2 cells producing a specific pattern of cytokines is tightly controlled and regulated by transcription factors. Thus down-regulation of mRNAlevels of a single transcription factor leads to a “knock-down” of several mediators simultaneously, representing an advantage compared to earlier approaches involving down-regulation of one intercellular inflammatory mediator, which is unlikely to influence all pathophysiological aspects of the disease. We review the impact of specific and master transcription factors involved in Th2 cell commitment and evaluate approaches for the down-regulation of these proteins by degradation of their mRNA using nucleic-acid based technologies including antisense oligonucleotides, ribozymes, DNAzymes, decoys oligonucleotides and RNA interference.
Export Options
About this article
Cite this article as:
Sel Serdar, Henke Wolfgang, Dietrich Alexander, Herz Udo and Renz Harald, Treatment of Allergic Asthma by Targeting Transcription Factors Using Nucleic-Acid Based Technologies, Current Pharmaceutical Design 2006; 12 (25) . https://dx.doi.org/10.2174/138161206778194150
DOI https://dx.doi.org/10.2174/138161206778194150 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact of Inhaled Corticosteroids on the Natural History of Asthma in Children
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Recent Patents on Influenza Vaccines
Recent Patents on Biotechnology Atherosclerosis is an Inflammatory Disorder After All
Current Topics in Medicinal Chemistry Calcium Metabolism & Hypercalcemia in Adults
Current Medicinal Chemistry The Clinical Pathway for Hypertensive Patient of Local Health Unit, Hospitals and General Practitioners, the Milan Experience
Reviews on Recent Clinical Trials A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer
Current Drug Targets Synthetic Glucocorticoids: Antenatal Administration and Long-term Implications
Current Pharmaceutical Design Enteric Ecosystem Disruption in Autism Spectrum Disorder: Can the Microbiota and Macrobiota be Restored?
Current Pharmaceutical Design G-Protein Coupled Receptors (GPCRs): A Comprehensive Computational Perspective
Combinatorial Chemistry & High Throughput Screening Lack of Data on Depression-like States and Antidepressant Pharmacotherapy in Patients with Epilepsy: Randomised Controlled Trials are Badly Needed
Current Pharmaceutical Design Association of Metabolic Syndrome and Asthma Status: A Prospective Study from Guilan Province, Iran
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review of Recent Patents on the ASICs as a Key Drug Target
Recent Patents on Biotechnology Controlled Parenteral Formulations: An Efficacious and Favourable Way to Deliver the Anti-psychotic Drugs
Current Psychiatry Research and Reviews The Role of Matrix Metalloproteinases in Chronic Pulmonary Diseases: Relevance of the Airway Epithelium
Current Respiratory Medicine Reviews ADAM8/MS2/CD156, an Emerging Drug Target in the Treatment of Inflammatory and Invasive Pathologies
Current Pharmaceutical Design Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
Current Medicinal Chemistry Lactobacillus Rhamnosus Cell Lysate in the Management of Resistant Childhood Atopic Eczema
Inflammation & Allergy - Drug Targets (Discontinued)